FY2027 Earnings Forecast for MLTX Issued By HC Wainwright

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Research analysts at HC Wainwright issued their FY2027 earnings estimates for MoonLake Immunotherapeutics in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($3.11) for the year. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share.

A number of other equities analysts have also commented on MLTX. Needham & Company LLC raised their price target on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. BTIG Research boosted their price objective on MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Oppenheimer increased their price objective on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Tuesday, February 24th. Royal Bank Of Canada lifted their target price on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the company a “sector perform” rating in a report on Monday. Finally, The Goldman Sachs Group cut MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and upped their price target for the company from $8.00 to $10.00 in a research report on Wednesday, January 14th. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $27.85.

MoonLake Immunotherapeutics Stock Up 0.1%

MoonLake Immunotherapeutics stock opened at $17.69 on Wednesday. MoonLake Immunotherapeutics has a 1-year low of $5.95 and a 1-year high of $62.75. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -5.03 and a beta of 1.20. The company has a current ratio of 9.27, a quick ratio of 9.27 and a debt-to-equity ratio of 0.24. The firm has a 50 day simple moving average of $15.80 and a 200 day simple moving average of $22.31.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.92). During the same quarter in the prior year, the business posted ($0.72) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Kestra Advisory Services LLC purchased a new stake in MoonLake Immunotherapeutics in the fourth quarter valued at approximately $26,000. FNY Investment Advisers LLC bought a new position in shares of MoonLake Immunotherapeutics in the 3rd quarter worth $28,000. Bank of America Corp DE raised its position in shares of MoonLake Immunotherapeutics by 64.7% during the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after buying an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of MoonLake Immunotherapeutics by 115.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after acquiring an additional 3,166 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of MoonLake Immunotherapeutics by 45.4% during the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after acquiring an additional 1,069 shares during the last quarter. 93.85% of the stock is currently owned by institutional investors.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 72,908 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total value of $1,052,062.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Da Silva Jorge Santos sold 70,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total value of $1,014,300.00. Following the sale, the chief executive officer owned 2,878,577 shares of the company’s stock, valued at approximately $41,710,580.73. This trade represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 402,908 shares of company stock valued at $5,987,162 in the last three months. 12.05% of the stock is owned by corporate insiders.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.